The FDA already rejected MDMA therapy in 2024 and demanded more trials. No psychedelic is positioned for approval this year — the regulatory bar is too high and the timeline too short.
No. The FDA got burned on MDMA’s weak trial data, and no psychedelic has a clean enough approval package lined up to cross the finish line this year.
The FDA just rejected MDMA for PTSD and demanded another massive trial. They are way too slow and bureaucratic to greenlight any psychedelic this year.
No chance. The FDA just shot down MDMA and nothing else is close enough to clear approval this year.
No. The FDA moves slow and final approval lags behind breakthroughs; this year won't crown a psychedelic as medicine.
No. Fortune favors the patient; this year the system won’t grant full medical approval of psychedelics.
Momentum from trials and regulator interest points to the first psychedelic medicine gaining FDA approval this year.
Not this year. FDA approval hasn't been granted for any psychedelic medicine yet; the trials look promising, but final sign-off isn't here.
No. The FDA moves slow with safety and proof; we must have certainty before opening a psychedelic medical door this year.
Regulators need solid Phase 3 data and safety. This year won’t clear the path for a full psychedelic approval.
No. The FDA won’t rush psychedelics; solid safety and efficacy take time, so this year won’t bring formal approvals.
Yes, darling, progress seduces regulators; strong trials could bow a psychedelic into approval this year.
Not this year; the FDA moves like a careful spark, and psychedelics are still in trials, not approved.
No. The FDA moves slow and demands robust, large trials. Psychedelics getting approved remains rare, and this year is unlikely.
No. In science, data and review take time; this year would be too soon for an FDA psychedelic approval.
Not this year. FDA approvals demand solid safety and long trials; psychedelics are still finding their path.
Yes. The FDA is fast-tracking psychedelic therapies, and the MDMA/psilocybin data are compelling enough for an approval this year.
